Triheptanoin--a medium chain triglyceride with odd chain fatty acids: a new anaplerotic anticonvulsant treatment?
- PMID: 21855298
- PMCID: PMC3422680
- DOI: 10.1016/j.eplepsyres.2011.05.023
Triheptanoin--a medium chain triglyceride with odd chain fatty acids: a new anaplerotic anticonvulsant treatment?
Abstract
The triglyceride of heptanoate (C7 fatty acid), triheptanoin, is a tasteless oil used to treat rare metabolic disorders in USA and France. Heptanoate is metabolized by β-oxidation to provide propionyl-CoA, which after carboxylation can produce succinyl-CoA, resulting in anaplerosis - the refilling of the tricarboxylic acid cycle. Heptanoate is also metabolized by the liver to the C5 ketones, β-ketopentanoate and/or β-hydroxypentanoate, which are released into the blood and thought to enter the brain via monocarboxylate transporters. Oral triheptanoin has recently been discovered to be reproducibly anticonvulsant in acute and chronic mouse seizures models. However, current knowledge on alterations of brain metabolism after triheptanoin administration and anaplerosis via propionyl-CoA carboxylation in the brain is limited. This review outlines triheptanoin's unique anticonvulsant profile and its clinical potential for the treatment of medically refractory epilepsy. Anaplerosis as a therapeutic approach for the treatment of epilepsy is discussed. More research is needed to elucidate the anticonvulsant mechanism of triheptanoin and to reveal its clinical potential for the treatment of epilepsy and other disorders of the brain.
Copyright © 2011 Elsevier B.V. All rights reserved.
Figures

Similar articles
-
Anticonvulsant effects of a triheptanoin diet in two mouse chronic seizure models.Neurobiol Dis. 2010 Dec;40(3):565-72. doi: 10.1016/j.nbd.2010.07.017. Epub 2010 Aug 4. Neurobiol Dis. 2010. PMID: 20691264 Free PMC article.
-
Triheptanoin in acute mouse seizure models.Epilepsy Res. 2012 May;99(3):312-7. doi: 10.1016/j.eplepsyres.2011.12.013. Epub 2012 Jan 20. Epilepsy Res. 2012. PMID: 22260920
-
Modification of Astrocyte Metabolism as an Approach to the Treatment of Epilepsy: Triheptanoin and Acetyl-L-Carnitine.Neurochem Res. 2016 Feb;41(1-2):86-95. doi: 10.1007/s11064-015-1728-5. Epub 2015 Oct 3. Neurochem Res. 2016. PMID: 26433381 Review.
-
Triheptanoin partially restores levels of tricarboxylic acid cycle intermediates in the mouse pilocarpine model of epilepsy.J Neurochem. 2014 Apr;129(1):107-19. doi: 10.1111/jnc.12610. Epub 2013 Dec 2. J Neurochem. 2014. PMID: 24236946
-
Alternative Fuels in Epilepsy and Amyotrophic Lateral Sclerosis.Neurochem Res. 2017 Jun;42(6):1610-1620. doi: 10.1007/s11064-016-2106-7. Epub 2016 Nov 21. Neurochem Res. 2017. PMID: 27868154 Review.
Cited by
-
M-Current Suppression, Seizures and Lipid Metabolism: A Potential Link Between Neuronal Kv7 Channel Regulation and Dietary Therapies for Epilepsy.Front Physiol. 2020 May 25;11:513. doi: 10.3389/fphys.2020.00513. eCollection 2020. Front Physiol. 2020. PMID: 32523549 Free PMC article. Review.
-
Metabolic perturbations associated with the consumption of a ketogenic medium-chain TAG diet in dogs with idiopathic epilepsy.Br J Nutr. 2018 Sep;120(5):484-490. doi: 10.1017/S0007114518001617. Epub 2018 Jul 13. Br J Nutr. 2018. PMID: 30001753 Free PMC article.
-
Triheptanoin Mitigates Brain ATP Depletion and Mitochondrial Dysfunction in a Mouse Model of Alzheimer's Disease.J Alzheimers Dis. 2020;78(1):425-437. doi: 10.3233/JAD-200594. J Alzheimers Dis. 2020. PMID: 33016909 Free PMC article.
-
Heptanoate as a neural fuel: energetic and neurotransmitter precursors in normal and glucose transporter I-deficient (G1D) brain.J Cereb Blood Flow Metab. 2013 Feb;33(2):175-82. doi: 10.1038/jcbfm.2012.151. Epub 2012 Oct 17. J Cereb Blood Flow Metab. 2013. PMID: 23072752 Free PMC article.
-
Anaplerotic triheptanoin diet enhances mitochondrial substrate use to remodel the metabolome and improve lifespan, motor function, and sociability in MeCP2-null mice.PLoS One. 2014 Oct 9;9(10):e109527. doi: 10.1371/journal.pone.0109527. eCollection 2014. PLoS One. 2014. PMID: 25299635 Free PMC article.
References
-
- Alvestad S, Hammer J, Eyjolfsson E, Qu H, Ottersen OP, Sonnewald U. Limbic structures show altered glial-neuronal metabolism in the chronic phase of kainate induced epilepsy. Neurochem. Res. 2008;33:257–266. - PubMed
-
- Bak LK, Iversen P, Sorensen M, Keiding S, Vilstrup H, Ott P, Waagepetersen HS, Schousboe A. Metabolic fate of isoleucine in a rat model of hepatic encephalopathy and in cultured neural cells exposed to ammonia. Metab. Brain Dis. 2009;24:135–145. - PubMed
-
- Ballhausen D, Mittaz L, Boulat O, Bonafe L, Braissant O. Evidence for catabolic pathway of propionate metabolism in CNS: expression pattern of methylmalonyl-CoA mutase and propionyl-CoA carboxylase alpha-subunit in developing and adult rat brain. Neuroscience. 2009;164:578–587. - PubMed
-
- Barton ME, Klein BD, Wolf HH, White HS. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 2001;47:217–227. - PubMed
-
- Blanco MM, dos Santos JG, Jr, Perez-Mendes P, Kohek SR, Cavarsan CF, Hummel M, Albuquerque C, Mello LE. Assessment of seizure susceptibility in pilocarpine epileptic and nonepileptic Wistar rats and of seizure reinduction with pentylenetetrazole and electroshock models. Epilepsia. 2009;50:824–831. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous